

Published in final edited form as:

*Psychopharmacology (Berl)*. 2014 September ; 231(17): 3325–3332. doi:10.1007/s00213-014-3546-x.

## Anticonvulsant Potencies of the Enantiomers of the Neurosteroids Androsterone and Etiocholanolone Exceed those of the Natural Forms

Dorota Zolkowska<sup>1</sup>, Ashish Dhir<sup>1,\*</sup>, Kathiresan Krishnan<sup>2</sup>, Douglas F. Covey<sup>2</sup>, and Michael A. Rogawski<sup>1</sup>

<sup>1</sup>Department of Neurology, University of California, Davis School of Medicine, Sacramento, California 20817

<sup>2</sup>Department of Developmental Biology, Washington University in St. Louis School of Medicine, St. Louis, Missouri 63110

### Abstract

**Rationale**—Androsterone [(3 $\alpha$ ,5 $\alpha$ )-3-hydroxyandrostane-17-one; 5 $\alpha$ ,3 $\alpha$ -A] and its 5 $\beta$ -epimer etiocholanolone [(3 $\alpha$ ,5 $\beta$ )-3-hydroxyandrostane-17-one; 5 $\beta$ ,3 $\alpha$ -A], the major excreted metabolites of testosterone, are neurosteroid positive modulators of GABA<sub>A</sub> receptors. Such neurosteroids typically show enantioselectivity in which the natural form is more potent than the corresponding unnatural enantiomer. For 5 $\alpha$ ,3 $\alpha$ -A and 5 $\beta$ ,3 $\alpha$ -A, the unnatural enantiomers are more potent at GABA<sub>A</sub> receptors than the natural forms.

**Objectives**—The aim of this study was to compare the anticonvulsant potencies and time courses of 5 $\alpha$ ,3 $\alpha$ -A and 5 $\beta$ ,3 $\alpha$ -A with their enantiomers in mouse seizure models.

**Methods**—Steroids were administered intraperitoneally to male NIH Swiss mice 15 min (or up to 6 h in time course experiments) prior to administration of an electrical stimulus in the 6-Hz or maximal electroshock (MES) seizure tests or the convulsant pentylenetetrazol (PTZ).

**Results**—In the 6-Hz test, the ED<sub>50</sub> values of *ent*-5 $\alpha$ ,3 $\alpha$ -A was 5.0 mg/kg whereas the value for 5 $\alpha$ ,3 $\alpha$ -A was 12.1 mg/kg; the corresponding values in the PTZ seizure test were 22.8 and 51.8 mg/kg. Neurosteroid GABA<sub>A</sub> receptor positive allosteric modulators are generally weak in the MES test and this was confirmed in the present study. However, the atypical relative potency relationship was maintained with ED<sub>50</sub> values of 140 and 223 mg/kg for *ent*-5 $\alpha$ ,3 $\alpha$ -A and 5 $\alpha$ ,3 $\alpha$ -A, respectively. Similar relationships were obtained for the 5 $\beta$ -isomers, except that the enantioselectivity was accentuated. In the 6-Hz and PTZ tests, the ED<sub>50</sub> values of *ent*-5 $\beta$ ,3 $\alpha$ -A were 11.8 and 20.4 mg/kg whereas the values for 5 $\beta$ ,3 $\alpha$ -A were 57.6 and 109.1 mg/kg. Protective activity in the 6-Hz test of *ent*-5 $\alpha$ ,3 $\alpha$ -A persisted for somewhat longer (~5 h) than for 5 $\alpha$ ,3 $\alpha$ -A (~4 h); protection by *ent*-5 $\beta$ ,3 $\alpha$ -A also persisted longer (~3 h) than for 5 $\beta$ ,3 $\alpha$ -A (~2 h).

Communicating author: Michael A. Rogawski, M.D., Ph.D., Department of Neurology, University of California, Davis, 4860 Y Street, Suite 3700, Sacramento, CA 95817; rogawski@ucdavis.edu.

\*Present address: Department of Biotechnology, Government of India, c/o Gujarat Forensic Sciences University, DFS Headquarters, Sector-18A, Near Police Bhavan, Gandhinagar, Gujarat, 382007, India

The authors declare no conflicts of interest.

**Conclusions**—The unnatural enantiomers of 17-keto androgen class neurosteroids have greater in vivo potency and a longer duration of action than their natural counterparts. The more prolonged duration of action of the unnatural enantiomers could reflect reduced susceptibility to metabolism. Unnatural enantiomers of androgen class neurosteroids could have therapeutic utility and may provide advantages over the corresponding natural isomers due to enhanced potency and improved pharmacokinetic characteristics.

### Keywords

androsterone; etiocholanolone; enantiomer; 6-Hz test; pentylenetetrazol test; maximal electroshock test

---

### Introduction

Certain endogenous steroid hormone metabolites are positive allosteric modulators of GABA<sub>A</sub> receptors at low concentrations and directly gate these receptors at higher concentrations (Lambert et al., 2009). As is the case for other agents that enhance inhibitory GABAergic function, such neurosteroids protect against seizures in diverse animal models, and there is emerging evidence that agents of this type are effective in the treatment of seizures and epilepsy in humans (Reddy and Rogawski, 2012; Bialer et al., 2013). The anticonvulsant potency of such steroids is closely correlated with their activity at GABA<sub>A</sub> receptors (Morrow et al., 1990; Kokate et al., 1994). Although the pregnanes allopregnanolone [(3 $\alpha$ ,5 $\alpha$ )-3-hydroxypregnan-20-one] and tetrahydrodeoxycorticosterone [(3 $\alpha$ ,5 $\alpha$ )-3,21-dihydroxypregnan-20-one] were the first endogenous GABA<sub>A</sub> receptor modulatory neurosteroids to be identified (Paul and Purdy, 1992), it is now recognized that a number of structurally related endogenous steroids have similar actions on GABA<sub>A</sub> receptors. In particular, the 17-ketosteroid androsterone (5 $\alpha$ ,3 $\alpha$ -A; Fig. 1) potentiates GABA<sub>A</sub> receptor responses albeit more weakly than allopregnanolone (Turner et al., 1989; Hawkinson et al., 1994; Anderson et al., 2000), and we demonstrated that it, as well as its 5 $\beta$ -epimer etiocholanolone (5 $\beta$ ,3 $\alpha$ -A), exhibit anticonvulsant activity in animal seizure models (Kaminski et al., 2005).

Most neurosteroids show enantioselectivity in which the natural form is more potent than the corresponding unnatural enantiomer. Notably, the enantiomers of allopregnanolone and its 5 $\beta$ -epimer pregnanolone are much less effective at potentiating GABA<sub>A</sub> receptor responses than the corresponding natural steroids (Wittmer et al., 1996; Covey et al., 2000; Covey, 2009). Recently, Katona et al. (2008) made the unexpected discovery that the enantiomers of androsterone and etiocholanolone (*ent*-5 $\alpha$ ,3 $\alpha$ -A and *ent*-5 $\beta$ ,3 $\alpha$ -A, respectively) are more potent than the natural steroids as (i) inhibitors of [<sup>35</sup>S]TBPS binding (a functional measure GABA<sub>A</sub> receptor activity), (ii) enhancers of rat  $\alpha_1\beta_2\gamma_2L$  GABA<sub>A</sub> receptor currents in *Xenopus laevis* oocytes, and (iii) anesthetics causing loss of righting reflex in tadpoles. As of yet, the enhanced potency of the enantiomers has not been verified in mammals. Therefore, in the present study we examined the activity of the enantiomers in comparison with their natural counterparts in mice in several seizure models. The metabolism of neurosteroids is complex and we reasoned that the enantiomers might be less susceptible to bioinactivation

or elimination than their natural counterparts. Accordingly, it was of interest to assess the time course of action of the enantiomers.

## Materials and methods

### Animals

Male NIH Swiss mice (22–30 g) were housed four per cage. Animals were kept in a vivarium under controlled laboratory conditions (temperature, 22–26 °C; humidity, 40–50%) with an artificial 12-h light/dark cycle and free access to food and water. Animals were allowed to acclimate to the vivarium for 5 days. The experiments were performed during the light phase of the light/dark cycle after a 30-min period of acclimation to the experimental room. Animals were maintained in facilities fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care, and all studies were performed under protocols approved by the University of California, Davis, Institutional Animal Care and Use Committee in strict compliance with the Guide for the Care and Use of Laboratory Animals of the National Research Council (National Academy Press, Washington, DC; <http://www.nap.edu/readingroom/books/labrats/>). Mice that survived testing were euthanized with CO<sub>2</sub>.

### Test substances and drug administration

Solutions of 5 $\alpha$ ,3 $\alpha$ -A, 5 $\beta$ ,3 $\alpha$ -A (Sigma-Aldrich, St. Louis, MO, U.S.A.) and *ent*-5 $\alpha$ ,3 $\alpha$ -A and *ent*-5 $\beta$ ,3 $\alpha$ -A (synthesized by K.K. in the laboratory of D.F.C.; see Katona et al., 2008) were made fresh daily in 40% hydroxypropyl- $\beta$ -cyclodextrin (Trappsol®; Cyclodextrin Technologies Development, High Springs, FL, U.S.A.) in sterile 0.9% saline. Further dilutions were made by using sterile saline. The convulsant agent pentylenetetrazol (PTZ; Sigma-Aldrich) was dissolved in saline immediately before use. All drug solutions were administered in a volume equaling 0.01 ml/g body weight. In the PTZ, 6-Hz and MES seizure tests, the steroids or vehicle were administered intraperitoneally 15 min before PTZ or electrical stimulation. The pretreatment interval was based on the time of maximal effect in the time-course experiment in the 6-Hz model (Fig. 3). Vehicle alone did not affect seizures in any of the models.

### 6-Hz electroshock seizure test

Testing was carried out as described previously (Kaminski et al., 2004). In brief, 3-s corneal stimulation (200- $\mu$ s duration, 32-mA monopolar rectangular pulses at 6 Hz) was delivered by a constant-current device (ECT Unit 5780; Ugo Basile, Comerio, Italy). Ocular anesthetic (0.5% tetracaine) was applied to the corneas 15 min before stimulation. Immediately before stimulation, the corneal electrodes were wetted with saline to provide good electrical contact. The seizures were often preceded by a period of intense locomotor agitation (wild running and jumping). The animals then exhibited a “stunned” posture associated with rearing (bipedal standing), forelimb automatic movements and clonus, twitching of the vibrissae, and Straub-tail. The duration of the seizure activity ranged from 60 to 120 s in untreated animals. Animals resumed their normal exploratory behavior after the seizure. The experimental end point was protection against the seizure: an animal was considered to be protected if it resumed its normal exploratory behavior within 10 s of stimulation.

### PTZ seizure test

Testing was carried out as previously described (Kokate et al., 1994). In brief, mice were injected subcutaneously with PTZ (80 mg/kg) and were observed for a 30-min period. Mice failing to show clonic seizures lasting >5 s were scored as protected.

### Maximal electroshock (MES) seizure test

Animals were subjected to a 0.2-s, 60-Hz electrical stimulus through corneal electrodes (as described earlier). The electroshock unit was adjusted to deliver a constant current of 50 mA. Animals failing to show tonic hindlimb extension were scored as protected (Kokate et al., 1994).

### Motor toxicity test

Steroids were evaluated for motor toxicity by using a modification of the horizontal screen test as described previously (Kokate et al., 1994). Mice were placed on a horizontally oriented grid (consisting of parallel 1.5-mm diameter rods situated 1 cm apart) and the grid was inverted. Animals that fell from the grid within 10 s were scored as impaired.

### Data analysis

To construct dose–response curves, steroids were tested at several doses spanning the dose producing 50% protection ( $ED_{50}$ ) or motor impairment ( $TD_{50}$ ).  $ED_{50}$  and  $TD_{50}$  values and their corresponding 95% confidence limits were determined by log-probit analysis using the Litchfield and Wilcoxon method (PHARM/PCS Version 4.2; Micro- Computer Specialists, Philadelphia, PA, U.S.A.). The protective index (PI), a measure of relative toxicity, was calculated as the ratio  $TD_{50}/ED_{50}$ . Half-time ( $t_{1/2}$ ) was estimated by non-linear single-exponential fits to the falling phase of the time-course data. The eudismic ratio was taken as the ratio of the  $ED_{50}$  or  $TD_{50}$  values of the less active enantiomer (distomer) to that of the more potent enantiomer (eutomer).

## Results

### 6-Hz test

In confirmation of our previous study (Kaminski et al., 2005), we found that pretreatment with  $5\alpha,3\alpha$ -A conferred protection in the 6-Hz test in a dose-dependent fashion (Fig. 2A). *Ent*- $5\alpha,3\alpha$ -A also conferred protection in a dose-dependent fashion, but was somewhat more potent (Fig. 2A and Table 1). Similarly,  $5\beta,3\alpha$ -A was effective in the 6-Hz test, but modestly less potent than its epimer  $5\alpha,3\alpha$ -A (Fig. 2B). The enantiomer *ent*- $5\beta,3\alpha$ -A was more potent than its natural counterpart.

We used the 6-Hz test to assess the time course of action of the steroids. As shown in Fig. 3A,  $5\alpha,3\alpha$ -A (100 mg/kg) conferred seizure protection in all animals at 5 min, the earliest time point tested, and substantial protection up to 45 min; protection dropped over the next 135 min and was no longer evident at 240 min. A lower dose of *ent*- $5\alpha,3\alpha$ -A (30 mg/kg) was used to achieve a similar degree of peak seizure protection. At this dose, nearly complete protection was achieved at time points up to 30 min. Protection then dropped at successive time points but protection was still evident at 300 min. Thus, the tail of the

response to the enantiomer was more prolonged than that of its natural counterpart even though a substantially lower dose was used. The fraction of animals protected at time points 2 h by *ent*-5 $\alpha$ ,3 $\alpha$ -A was significantly greater than those protected by 5 $\alpha$ ,3 $\alpha$ -A ( $p=0.048$  by Fisher's exact test). The  $t_{1/2}$  values for 5 $\alpha$ ,3 $\alpha$ -A and *ent*-5 $\alpha$ ,3 $\alpha$ -A were  $67.1 \pm 10.0$  min and  $80.6 \pm 13.9$  min, respectively.

Fig. 3B show time course results with various doses of the epimer 5 $\beta$ ,3 $\alpha$ -A. The higher doses (150 and 125 mg/kg) produced substantial protection up to 45 min: the highest dose conferred full protection from 10 to 45 min, whereas the 125 mg/kg was modestly less effective, peaking at 94 percent at 15 min. Seizure protection with the lowest dose (100 mg/kg) also peaked at 15 min but the maximum protection achieved was only 75 percent. A lower dose of *ent*-5 $\beta$ ,3 $\alpha$ -A (30 mg) chosen to just achieve full seizure protection, exhibited 100 percent protection at 10 min. Seizure protection then fell progressively but was still evident at 180 min. Therefore, *ent*-5 $\beta$ ,3 $\alpha$ -A even at the substantially lower dose had a slightly more prolonged duration of action although the difference did not reach statistical significance. The  $t_{1/2}$  values for 5 $\alpha$ ,3 $\alpha$ -A (125 mg/kg) and *ent*-5 $\alpha$ ,3 $\alpha$ -A were  $55.0 \pm 11.7$  min and  $72.4 \pm 46.2$  min, respectively.

### PTZ seizure test

As in our earlier study (Kaminski et al., 2005), 5 $\beta$ ,3 $\alpha$ -A and 5 $\beta$ ,3 $\alpha$ -A conferred protection in the PTZ seizure test in a dose-dependent fashion (Fig. 4). The enantiomers also conferred dosedependent protection but were considerably more potent (Fig. 4; Table 1).

### MES test

GABA<sub>A</sub> receptor active neurosteroids generally have low potency in the MES test (Kokate et al., 1994). The 17-ketosteroids are no different in this regard (Kaminski et al., 2005). As was the case in the other seizure models, the enantiomers were more potent than their natural counterparts in the MES test (Fig. 5; Table 1).

### Motor toxicity

All of the steroids caused motor impairment in the horizontal screen test (Table 1). As in the seizure tests, the enantiomers were more potent than their corresponding natural analogs for inducing positive effects in the horizontal screen test. Doses causing motor impairment were greater than those effective in the 6-Hz and PTZ test but lower than those effective the MES test. We calculated the "protective index" ( $PI = TD_{50}/ED_{50}$ ) as a measure of the separation between the dose protecting against seizures and the toxic dose. For each natural steroid and its enantiomer, the PI values in the various models were similar.

## Discussion

The 17-ketosteroids androsterone (5 $\alpha$ ,3 $\alpha$ -A) and its 5 $\beta$ -epimer etiocholanolone (5 $\beta$ ,3 $\alpha$ -A), the major excreted metabolites of testosterone, are weak positive modulators of GABA<sub>A</sub> receptors. In contrast to other A-ring reduced steroids with GABA<sub>A</sub> receptor modulatory activity, Katona et al. (2008) reported that the enantiomers *ent*-5 $\alpha$ ,3 $\alpha$ -A and *ent*-5 $\beta$ ,3 $\alpha$ -A were more potent than their natural counterparts as functional modulators of GABA<sub>A</sub>

receptors and also as anesthetics in *Xenopus laevis* tadpoles. A recent study indicated that GABA<sub>A</sub> receptor modulation by the *ent*-forms occurs at the same interaction site in the transmembrane domain of the  $\alpha$ -subunit where the natural steroids act (Hosie et al., 2009; Krishnan et al., 2012). Interestingly, the *ent*-steroids appear to bind co-planar in a “flipped” orientation relative to their natural counterparts, with the hydroxy groups at position 3 in both molecules (which are critical for activity at GABA<sub>A</sub> receptors) situated so that they can interact with the same site on the protein receptor.

We now confirm the atypical potency relationship between the enantiomers of the androsterone epimers and their natural counterparts. We used the 6-Hz test and the PTZ seizure test, which are sensitive to GABA<sub>A</sub> receptor positive modulatory neurosteroids (Kokate et al., 1994; Kaminski et al., 2004). In addition, we used the MES test, which is a widely used and well-accepted model to identify antiseizure agents (Krall et al., 1978). In the three mouse seizure models and in a test of motor impairment, which reflects sedation or muscle relaxation, the unnatural enantiomers were more potent than their natural counterparts. The eudismic ratio, a measure of the degree of enantioselectivity in the specific test (Lehmann et al., 1976), ranged from 1.6 to 5.3 (Table 2). As previously reported for the androgen derived A-ring reduced steroids (Kaminski et al., 2005) and also for other structurally related steroids (Kokate et al., 1994) with GABA<sub>A</sub> receptor activity, the  $\alpha$ -orientation of the 5-H is generally preferred to the  $\beta$ -orientation, but only modestly so. This relationship is less clear for the enantiomers. While *ent*-5 $\alpha$ ,3 $\alpha$ -A was possibly slightly more potent than *ent*-5 $\beta$ ,3 $\alpha$ -A in the tadpole assay and in the 6-Hz test, this was not the case for the other tests. A relationship of note that is similar in the present study in mice to that of the previous work in vitro and in tadpoles is that the enantioselectivity of the 5 $\beta$ -enantiomers exceeds that of the 5 $\alpha$ -enantiomers. Thus, in all four tests, the eudismic ratio of the 5 $\beta$ -enantiomers is greater than that of the 5 $\alpha$ -enantiomers (Table 2), suggesting that *ent*-5 $\beta$ ,3 $\alpha$ -A has higher complementarity to its receptor target than does *ent*-5 $\alpha$ ,3 $\alpha$ -A.

The correspondence in the structure-activity relationships (SAR) observed in the present study and the SAR in the prior study of functional effects on GABA<sub>A</sub> receptors in vitro (Katona et al., 2008) is consistent with the conclusion that the steroids exert their protective activity in the seizure and motor toxicity tests through effects on GABA<sub>A</sub> receptors. Prior SAR studies have similarly found that the relative potency ranking of GABA<sub>A</sub> receptor modulating neurosteroids in the PTZ and 6-Hz tests is closely related to their potencies as GABA<sub>A</sub> receptor modulators assessed by patch clamp recording in vitro (Kokate et al., 1994; Kaminski et al., 2004; 2005). The results of the present study bolster the conclusion that the anticonvulsant and sedative actions of GABA<sub>A</sub> receptor modulatory neurosteroids and their analogs occurs through effects on GABA<sub>A</sub> receptors.

While the natural 17-ketosteroids are generally weaker than other GABA<sub>A</sub> receptor modulatory neurosteroids in in vivo seizure tests, the unnatural enantiomers had potencies comparable to the most potent known neurosteroids, including allopregnanolone and its synthetic 3 $\beta$ -methyl analog ganaxolone, which is in clinical development for the treatment of epilepsy (Kaminski et al., 2005; Bialer et al., 2013). In the 6-Hz test, *ent*-5 $\alpha$ ,3 $\alpha$ -A was slightly more potent than ganaxolone (ED<sub>50</sub>, 6.3 mg/kg) and ~3-fold more potent than allopregnanolone (ED<sub>50</sub>, 14.2 mg/kg; Kaminski et al., 2004), whereas in the PTZ test,

*ent*-5 $\alpha$ ,3 $\alpha$  was modestly weaker than either ganaxolone or allopregnanolone (Reddy and Rogawski, 2000; Kokate et al., 1994). In general, GABA<sub>A</sub> receptor modulating neurosteroids have been found to exhibit similar potencies in the 6-Hz and PTZ tests (Kaminski et al., 2004). The reason for the relatively weaker activity in the PTZ test compared with the 6-Hz test in the present study is not apparent.

A particularly interesting outcome of the present study is the observation that the *ent*-forms were more potent in the MES test than their natural counterparts despite the fact that all steroids tested in this model were relatively weakly active. In the past, we have obtained results suggesting that the weak activity of certain GABA<sub>A</sub> receptor modulating neurosteroids in the MES test could be due to off-target pharmacological effects distinct from their actions on GABA<sub>A</sub> receptors (Kokate et al., 1999; Reddy and Rogawski, 2002). Agents with protective activity in the MES test often modulate voltage-gated sodium channels raising the possibility that they or another MES-relevant target could play a role. However, the corresponding enantioselectivity of the 17-ketosteroids in the MES test and for functional effects on GABA<sub>A</sub> receptors strongly suggests that for these steroids GABA<sub>A</sub> receptors are the relevant molecular target conferring activity in the MES test. This conclusion is likely generalizable to other GABA<sub>A</sub> modulatory neurosteroids, supporting the view that protective activity in the MES test, albeit weak, is truly due to effects on GABA<sub>A</sub> receptors.

An important characteristic of the *ent*-forms is that equieffective doses had more prolonged durations of action than their natural counterparts. All of the steroids exhibited peak responses from 5 to 15 min after administration. However, the durations of action differed. Thus, *ent*-5 $\alpha$ ,3 $\alpha$ -A at a dose (30 mg/kg) that produced full protection in the 6 Hz test exhibited some degree of protection for about ~5 h ( $t_{1/2}$ , 80.6 min) whereas 5 $\alpha$ ,3 $\alpha$ -A at a dose (100 mg/kg) that exhibited similar peak protective activity conferred protection for only ~3 h ( $t_{1/2}$ , 67.1 min) (see also Kaminski et al., 2005). Similarly, *ent*-5 $\beta$ ,3 $\alpha$ -A had protective activity that persisted about ~3 h ( $t_{1/2}$ , 72.4 min) whereas for 5 $\beta$ ,3 $\alpha$ -A protection persisted ~2 h ( $t_{1/2}$ , 55.0 min for 125 mg/kg group). The natural forms of the 17-ketosteroids exhibit a duration of action comparable to other structurally similar neurosteroids such as allopregnanolone and tetrahydrodeoxycorticosterone (Kokate et al., 1994; Reddy and Rogawski, 2002; Kaminski et al., 2005). We speculate that the more prolonged duration of action of the unnatural enantiomers reflects their reduced susceptibility to metabolism by steroid metabolic enzymes. Alternatively, the prolonged duration of action could be due to differences in distribution or elimination or to conversion of the longer acting steroids into active metabolites.

All steroids evaluated in the present study produced motor impairment at doses that were greater than those conferring seizure protection in the 6-Hz and PTZ tests but at lower doses than were effective in the MES test. The PI values reported in Table 1 provide a measure of the separation between the doses conferring therapeutic efficacy and adverse effects. The PI values of the 17-ketosteroids and their enantiomers are comparable to those obtained with other steroids acting on the GABA<sub>A</sub> receptor such as the pregnane steroids allopregnanolone and tetrahydrodeoxycorticosterone and their 5 $\beta$ -epimers (Kokate et al., 1994). In our prior study, the 5 $\alpha$ -pregnane steroids had modestly greater PI values than their 5 $\beta$ -epimers. A

similar situation applies for the 17-ketosteroids. It is noteworthy that despite the enhanced potency of the *ent*-steroids, they do not provide an improvement in PI. The PI values for both natural steroids are similar to those of the corresponding enantiomer.

In conclusion, the present study confirms the greater potency of the unnatural enantiomers of 17-keto androgen class neurosteroids in several in vivo mouse models. We have found that in addition to greater potency, the eutomers have more prolonged durations of action likely as a result of greater metabolic stability. Unnatural enantiomers of such steroids could have therapeutic utility and may provide advantages over the corresponding natural isomers due to enhanced potency and improved pharmacokinetic characteristics.

## Acknowledgments

Supported in part by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under award number NS079202 (M.A.R.) and the National Institute of General Medical Sciences of the National Institutes of Health under award number GM47969 (D.F.C.). The experiments were conducted in compliance with all applicable laws and regulations.

## Abbreviations


<b>5<math>\alpha</math>,3<math>\alpha</math>-A</b>	androsterone
<b>5<math>\beta</math>,3<math>\alpha</math>-A</b>	etiocholanolone
<b><i>ent</i>-5<math>\alpha</math>,3<math>\alpha</math>-A</b>	<i>ent</i> -androsterone
<b><i>ent</i>-5<math>\beta</math>,3<math>\alpha</math>-A</b>	<i>ent</i> -etiocholanolone
<b>PTZ</b>	pentylenetetrazol
<b>MES</b>	maximal electroshock
<b>PI</b>	protective index
<b>SAR</b>	structure-activity relationship

## References


- Anderson A, Boyd AC, Clark JK, Fielding L, Gemmell DK, Hamilton NM, Maidment MS, May V, McGuire R, McPhail P, Sansbury FH, Sundaram H, Taylor R. Conformationally constrained anesthetic steroids that modulate GABA<sub>A</sub> receptors. *J Med Chem.* 2000; 43:4118–4125. [PubMed: 11063608]
- Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI). *Epilepsy Res.* 2013; 103:2–30. [PubMed: 23219031]
- Covey DF. *ent*-Steroids: novel tools for studies of signaling pathways. *Steroids.* 2009; 74:577–585. [PubMed: 19103212]
- Covey DF, Nathan D, Kalkbrenner M, Nilsson KR, Hu Y, Zorumski CF, Evers AS. Enantioselectivity of pregnanolone-induced  $\gamma$ -aminobutyric acid<sub>A</sub> receptor modulation and anesthesia. *J Pharmacol Exp Ther.* 2000; 293:1009–1016. [PubMed: 10869405]
- Hawkinson JE, Kimbrough CL, Belevi D, Lambert JJ, Purdy RH, Lan NC. Correlation of neuroactive steroid modulation of [<sup>35</sup>S]*t*-butylbicyclophosphorothionate and [<sup>3</sup>H]flunitrazepam binding and  $\gamma$ -aminobutyric acid<sub>A</sub> receptor function. *Mol Pharmacol.* 1994; 46:977–985. [PubMed: 7969089]
- Hosie AM, Clarke L, da Silva H, Smart TG. Conserved site for neurosteroid modulation of GABA<sub>A</sub> receptors. *Neuropharmacology.* 2009; 6:149–154. [PubMed: 18762201]




- Kaminski RM, Livingood MR, Rogawski MA. Allopregnanolone analogs that positively modulate GABA<sub>A</sub> receptors protect against partial seizures induced by 6 Hz electrical stimulation in mice. *Epilepsia*. 2004; 45:1–4.
- Kaminski RM, Marini H, Kim WJ, Rogawski MA. Anticonvulsant activity of androsterone and etiocholanolone. *Epilepsia*. 2005; 46:819–827. [PubMed: 15946323]
- Katona BW, Krishnan K, Cai ZY, Manion BD, Benz A, Taylor A, Evers AS, Zorumski CF, Mennerick S, Covey DF. Neurosteroid analogues. 12. Potent enhancement of GABA<sub>A</sub> mediated chloride currents at GABA<sub>A</sub> receptors by *ent*-androgens. *Eur J Med Chem*. 2008; 43:107–113. [PubMed: 17434649]
- Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA. Finasteride, a 5 $\alpha$ -reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. *J Pharmacol Exp Ther*. 1999; 288:679–684. [PubMed: 9918575]
- Kokate TG, Svensson BE, Rogawski MA. Anticonvulsant activity of neurosteroids: correlation with  $\gamma$ -aminobutyric acid evoked chloride current potentiation. *J Pharmacol Exp Ther*. 1994; 270:1223–1229. [PubMed: 7932175]
- Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: II. Anticonvulsant drug screening. *Epilepsia*. 1978; 19:409–428. [PubMed: 699894]
- Krishnan K, Manion BD, Taylor A, Bracamontes J, Steinbach JH, Reichert DE, Evers AS, Zorumski CF, Mennerick S, Covey DF. Neurosteroid analogues. 17. Inverted binding orientations of androsterone enantiomers at the steroid potentiation site on  $\gamma$ -aminobutyric acid type A receptors. *J Med Chem*. 2012; 55:1334–1345. [PubMed: 22191644]
- Lambert JJ, Cooper MA, Simmons RD, Weir CJ, Belelli D. Neurosteroids: endogenous allosteric modulators of GABA<sub>A</sub> receptors. *Psychoneuroendocrinology*. 2009; 34(Suppl 1):S48–58. [PubMed: 19758761]
- Lehmann FPA, Rodrigues de Miranda JF, Ariens EJ. Stereoselectivity and affinity in molecular pharmacology. *Prog Drug Res*. 1976; 20:101–142. [PubMed: 13457]
- Morrow AL, Pace JR, Purdy RH, Paul SM. Characterization of steroid interactions with  $\gamma$ -aminobutyric acid receptor-gated chloride ion channels: evidence for multiple steroid recognition sites. *Mol Pharmacol*. 1990; 37:263–270. [PubMed: 1689453]
- Paul SM, Purdy RH. Neuroactive steroids. *FASEB J*. 1992; 6:2311–2322. [PubMed: 1347506]
- Reddy DS, Rogawski MA. Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy. *J Pharmacol Exp Ther*. 2000; 294:909–915. [PubMed: 10945840]
- Reddy DS, Rogawski MA. Stress-induced deoxycorticosterone-derived neurosteroids modulate GABA<sub>A</sub> receptor function and seizure susceptibility. *J Neurosci*. 2002; 22:3795–3805. [PubMed: 11978855]
- Reddy, DS.; Rogawski, MA. Neurosteroids – Endogenous regulators of seizure susceptibility and role in the treatment of epilepsy (Chapter 77). In: Noebels, JL.; Avoli, M.; Rogawski, MA.; Olsen, RW.; Delgado-Escueta, AV., editors. *Jasper’s basic mechanisms of the epilepsies*. 4. Oxford University Press; 2012. p. 984-1002.
- Turner DM, Ransom RW, Yang JS, Olsen RW. Steroid anesthetics and naturally occurring analogs modulate the  $\gamma$ -aminobutyric acid receptor complex at a site distinct from barbiturates. *J Pharmacol Exp Ther*. 1989; 248:960–966. [PubMed: 2539464]
- Wittmer LL, Hu Y, Kalkbrenner M, Evers AS, Zorumski CF, Covey DF. Enantioselectivity of steroid-induced  $\gamma$ -aminobutyric acid<sub>A</sub> receptor modulation and anesthesia. *Mol Pharmacol*. 1996; 50:1581–1586. [PubMed: 8967980]




**Fig. 1.** Structures of the natural 17-keto androgen class neurosteroids androsterone and etiocholanolone and their unnatural enantiomers.

**Fig. 2.**


A, Dose–response relationships for protective activity of androsterone (5 $\alpha$ ,3 $\alpha$ -A) and *ent*androsterone (*ent*-5 $\alpha$ ,3 $\alpha$ -A) in the 6-Hz seizure test. Steroids were administered 15 min before electrical stimulation. Data points indicate percentage of animals protected. Each point represents eight mice. B, Dose–response relationship for protective activity of etiocholanolone (5 $\beta$ ,3 $\alpha$ -A) and *ent*-etiocholanolone (*ent*-5 $\beta$ ,3 $\alpha$ -A) in the 6-Hz test. Each point represents eight mice.

**Fig. 3.**

A, Time course for protection by  $5\alpha,3\alpha\text{-A}$  and  $ent\text{-}5\alpha,3\alpha\text{-A}$  at doses of 100 and 30 mg/kg respectively in the 6-Hz (32 mA, 3 s) seizure test. The interval between the steroid injection and the electrical stimulus is plotted on the abscissa and the percentage of animals protected against seizures is plotted on the ordinate. B, Time course for protection by  $5\beta,3\alpha\text{-A}$  at a doses of 150, 125, 100 mg/kg and  $ent\text{-}5\beta,3\alpha\text{-A}$  at a dose of 30 mg/kg in the 6-Hz test. Each point represents at least eight mice. Curves are arbitrary fits to the data; the curve representing  $5\beta,3\alpha\text{-A}$  is to the 100 mg/kg group.

**Fig. 4.**

A, Dose–response relationship for protective activity of 5 $\alpha$ ,3 $\alpha$ -A and *ent*-5 $\alpha$ ,3 $\alpha$ -A in the pentylenetetrazol (PTZ) test. Steroids were administered 15 min before injection of PTZ. Data points indicate percentage of animals protected against clonic seizures. Each point represents eight mice. B, Dose–response relationship for protective activity of 5 $\beta$ ,3 $\alpha$ -A and *ent*-5 $\beta$ ,3 $\alpha$ -A in the PTZ test. Each point represents eight to ten mice.



**Fig. 5.**

A, Dose–response relationships for protection by 5 $\alpha$ ,3 $\alpha$ -A and ent-5 $\alpha$ ,3 $\alpha$ -A in the maximal electroshock (MES; 50 mA, 0.2 s, 60 Hz) test. Steroids were administered 15 min before electrical stimulation. Data points indicate percentage of animals protected against seizures. Each point represents eight mice. B, Dose–response relationships for protection by 5 $\beta$ ,3 $\alpha$ -A and ent-5 $\beta$ ,3 $\alpha$ -A in the MES test. Each point represents eight mice.

**Table 1**

ED<sub>50</sub> values of androsterone (5 $\alpha$ ,3 $\alpha$ -A), *ent*-androsterone (*ent*-5 $\alpha$ ,3 $\alpha$ -A), etiocholanolone (5 $\beta$ ,3 $\alpha$ -A) and *ent*-etiocholanolone (*ent*-5 $\beta$ ,3 $\alpha$ -A) for protection in the 6-Hz electrical stimulation, pentylenetetrazol (PTZ) and maximal electroshock (MES) seizure tests in mice

Steroid	ED <sub>50</sub> (95% confidence intervals), mg/kg <sup>a</sup>		
	[PI <sup>b</sup> ]		
	6-Hz	PTZ	MES
5 $\alpha$ ,3 $\alpha$ -A	12.10 (6.04–24.30) [15.13]	51.80 (32.57–82.46) [3.53]	222.90 (180.20–275.80) [0.82]
<i>ent</i> -5 $\alpha$ ,3 $\alpha$ -A	4.95 (1.40–17.60) [14.18]	22.80 (18.40–28.10) [3.08]	140.10 (115.13–170.43) [0.50]
5 $\beta$ ,3 $\alpha$ -A	57.57 (39.60–83.70) [2.61]	109.07 (100.31–118.60) [1.37]	177.07 (118.34–264.94) [0.85]
<i>ent</i> -5 $\beta$ ,3 $\alpha$ -A	11.78 (5.98–23.20) [3.07]	20.38 (13.70–30.32) [1.78]	89.87 (79.05–102.16) [0.40]

<sup>a</sup>ED<sub>50</sub> values (with 95% confidence intervals in parentheses) represent the dose in mg/kg that is estimated to protect 50% of animals.

<sup>b</sup>PI (protective index) is the ratio between TD<sub>50</sub> (the dose estimated to produce motor impairment in 50% of animals in the horizontal screen test) value and the ED<sub>50</sub> value. The TD<sub>50</sub> values (95% confidence intervals) for 5 $\alpha$ ,3 $\alpha$ -A and *ent*-5 $\alpha$ ,3 $\alpha$ -A were 183.1 (136.5–245.8) mg/kg and 70.2 (42.6–115.6) mg/kg, respectively. The TD<sub>50</sub> values for 5 $\beta$ ,3 $\alpha$ -A and *ent*-5 $\beta$ ,3 $\alpha$ -A were 150.0 (84.1–267.4) mg/kg and 36.2 (24.1–54.4) mg/kg, respectively.

**Table 2**

Eudismic ratios for enantiomer pairs in the seizure tests and the test of motor toxicity

Enantiomer Pairs	Eudismic Ratio <sup>a</sup>			
	6-Hz <sup>b</sup>	PTZ <sup>b</sup>	MES <sup>b</sup>	Horizontal Screen <sup>c</sup>
5 $\alpha$ ,3 $\alpha$ -A– <i>ent</i> -5 $\alpha$ ,3 $\alpha$ -A	2.4	2.3	1.6	2.6
5 $\beta$ ,3 $\alpha$ -A– <i>ent</i> -5 $\beta$ ,3 $\alpha$ -A	4.9	5.3	2.0	4.1

<sup>a</sup>Ratio of the ED<sub>50</sub> or TD<sub>50</sub> values from Table 1 of distomer (natural steroids) to that of eutomer (*ent*steroids).

<sup>b</sup>Seizure tests.

<sup>c</sup>Test of motor toxicity reflecting sedation or muscle relaxation.